# Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

> **NCT02129062** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 3 (actual)

## Conditions studied

- Adult B Acute Lymphoblastic Leukemia
- Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1
- Recurrent Adult Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** Ibrutinib
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT02129062
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-04
- **Primary completion:** 2015-11
- **Final completion:** 2015-11
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Slow accrual.
- **Last updated:** 2017-01-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02129062

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02129062, "Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02129062. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*